DK1820506T3 - Dipyridamol-formuleringer med forlænget frigivelse og fremgangsmåde til fremstilling heraf - Google Patents

Dipyridamol-formuleringer med forlænget frigivelse og fremgangsmåde til fremstilling heraf

Info

Publication number
DK1820506T3
DK1820506T3 DK06250764T DK06250764T DK1820506T3 DK 1820506 T3 DK1820506 T3 DK 1820506T3 DK 06250764 T DK06250764 T DK 06250764T DK 06250764 T DK06250764 T DK 06250764T DK 1820506 T3 DK1820506 T3 DK 1820506T3
Authority
DK
Denmark
Prior art keywords
formulation
extended release
preparation
release dipyridamole
formulations
Prior art date
Application number
DK06250764T
Other languages
English (en)
Inventor
Minutza Leibovici
Itamar Kanari
Michael Fox
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of DK1820506T3 publication Critical patent/DK1820506T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK06250764T 2006-02-09 2006-02-13 Dipyridamol-formuleringer med forlænget frigivelse og fremgangsmåde til fremstilling heraf DK1820506T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77225706P 2006-02-09 2006-02-09

Publications (1)

Publication Number Publication Date
DK1820506T3 true DK1820506T3 (da) 2008-07-07

Family

ID=36384355

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06250764T DK1820506T3 (da) 2006-02-09 2006-02-13 Dipyridamol-formuleringer med forlænget frigivelse og fremgangsmåde til fremstilling heraf

Country Status (14)

Country Link
US (1) US20070184110A1 (da)
EP (1) EP1820506B1 (da)
JP (1) JP2008534681A (da)
CN (1) CN101365453A (da)
AT (1) ATE390138T1 (da)
AU (1) AU2006337643A1 (da)
CA (1) CA2640472A1 (da)
DE (1) DE602006000819T2 (da)
DK (1) DK1820506T3 (da)
ES (1) ES2303314T3 (da)
HK (1) HK1104791A1 (da)
IL (1) IL193023A0 (da)
PT (1) PT1820506E (da)
WO (1) WO2007092026A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090196935A1 (en) * 2008-02-01 2009-08-06 Ahmed Salah U Pharmaceutical Capsules Comprising Extended Release Dipyridamole Pellets
WO2009100534A1 (en) * 2008-02-14 2009-08-20 Kardiatech, Inc. Combination therapy to treat vascular disorders
US20100069326A1 (en) * 2008-02-14 2010-03-18 Wasimul Haque Combination Therapies to Treat Cardio- and Cerebro-Vascular Disorders
US20120141584A1 (en) * 2009-08-26 2012-06-07 Aptapharma, Inc. Multilayer Minitablets
CN101780037B (zh) * 2010-02-03 2011-11-16 南昌大学 双嘧达莫自乳化给药系统及其制备方法
CN101919822B (zh) * 2010-07-16 2013-10-23 钟术光 综合性能改善的片剂及其制备方法
PT2704698T (pt) * 2011-05-05 2019-11-19 Hennig Arzneimittel Gmbh&Co Kg Forma farmacêutica para a libertação controlada de princípios activos
EP2817000B1 (en) 2012-02-21 2021-08-04 Towa Pharmaceutical Europe, S.L. Oral pharmaceutical compositions of dabigatran etexilate
CN103417494B (zh) * 2013-08-13 2015-12-23 杭州高成生物营养技术有限公司 一种以酒石酸作为主要成分的微丸
BR122019024673B1 (pt) 2013-12-04 2023-04-11 Boehringer Ingelheim Vetmedica Gmbh Composições farmacêuticas aprimoradas de pimobendan
CN105106225A (zh) * 2015-09-10 2015-12-02 石家庄市智同医药科技有限公司 一种复方双嘧达莫阿司匹林片剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3031450A (en) * 1959-04-30 1962-04-24 Thomae Gmbh Dr K Substituted pyrimido-[5, 4-d]-pyrimidines
DE2831164A1 (de) * 1978-07-15 1980-01-24 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
CH647676A5 (fr) * 1978-12-22 1985-02-15 Donald E Panoz Formes galeniques a usage oral, a liberation programmee et leurs procedes de preparation.
DE3000979A1 (de) 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
EP0169465B1 (de) 1984-07-21 1990-02-28 Hoechst Aktiengesellschaft Kombinationspräparat aus Pyrimido-pyrimidinen und O-Acetylsalicylsäure bzw. deren pharmakologisch verträglichen Salzen und dessen Verwendung
DE3627423A1 (de) * 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
US6376242B1 (en) * 1999-09-21 2002-04-23 Emory University Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration

Also Published As

Publication number Publication date
CA2640472A1 (en) 2007-08-16
US20070184110A1 (en) 2007-08-09
DE602006000819D1 (de) 2008-05-08
EP1820506B1 (en) 2008-03-26
ATE390138T1 (de) 2008-04-15
EP1820506A1 (en) 2007-08-22
PT1820506E (pt) 2008-05-23
DE602006000819T2 (de) 2009-04-09
WO2007092026A1 (en) 2007-08-16
HK1104791A1 (en) 2008-01-25
AU2006337643A1 (en) 2007-08-16
CN101365453A (zh) 2009-02-11
ES2303314T3 (es) 2008-08-01
JP2008534681A (ja) 2008-08-28
IL193023A0 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
DK1820506T3 (da) Dipyridamol-formuleringer med forlænget frigivelse og fremgangsmåde til fremstilling heraf
AR062000A1 (es) Formulaciones de modificador de respuesta inmune
CA3094580C (en) Oral formulations of cytidine analogs and methods of use thereof
FI20055568A (fi) Menetelmä karboksyylihappoesteriseoksien valmistamiseksi ja niiden käyttö
MX2009004203A (es) Combinaciones de paracetamol/ibuprofeno y metodo para su uso.
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
IT1362675B (it) N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche
WO2009121945A3 (en) Dpp-iv inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
PL1916994T3 (pl) Wytwarzanie kompozycji farmaceutycznej o szybkim uwalnianiu leków nierozpuszczalnych w wodzie i kompozycje farmaceutyczne otrzymywane sposobem według wynalazku
WO2007014124A3 (en) High drug load formulations and dosage forms
CL2008000981A1 (es) Compuestos derivados de imidazolidin-carboxamida; composicion farmaceutica; procedimiento de produccion de la composicion farmaceutica; y uso en el tratamiento y/o prevencion de trastornos ateroscleroticos, de metabolismo de acidos grasos y en los qu
DK200900115U1 (en) Novel pharmaceutical modified release dosage form cyclooxygenase enzyme inhibitor
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
MX2009012782A (es) Formulaciones para administracion oral de agentes terapeuticos y metodos relacionados.
IL201465A0 (en) Self-precipitating pharmaceutical formulations for the modified release of active principle
TN2010000135A1 (en) Galenical formulations of organic compounds
ITFI20050041A1 (it) Idrossammati come inibitori dell'istone deacelitasi, loro preparazione e formulazioni farmaceutiche che li contengono
UA96794C2 (ru) Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе
DE602006011127D1 (de) Fettsäure-benzenediol-derivate sowie herstellungs- und verwendungsverfahren dafür
NO20083183L (no) Fast farmasoytisk sammensetning inneholdende irbesartan
IL185723A0 (en) Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same
EP2196463A4 (en) PREPARATION OF 5,6-DIMETHYLXANTHONE-4-ACETIC ACID, DERIVATIVES DERIVATED THEREOF AND PHARMACEUTICAL FORMULATIONS THEREOF
NO20070187L (no) Oralt desintegrerende farmasoytisk preparat omfattende risperidon
ATE530172T1 (de) Pharmazeutische formulierungen mit clopidogrel
CL2007002807A1 (es) Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren